← boardnext 2028-04
PRLD
Prelude Therapeuticsdistress 6/10 · elevated risk$3.86-2%today-30% from 52w high
Oncology 4
Lead: SMARCA4-mutated cancers · target PD-1
Revenue
pre-revenue
Liquidity
$82M
Runway
1.9 yrs
Shares 1y
+41%
Price & events
+74.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
-7.7%
1W
-11.9%
1M
-12.3%
3M
+91.1%
6M
+324.2%
1Y
-37.3%
2Y
-88.7%
5Y
-94.3%
All
Overview
- Market Cap
- $307.43M
- Volume
- 31.14K
- 52 Week Range
- $0.78 – $5.52
- Total Shares
- 79.65M
- Float Shares
- 27.59M
- Short %
- 11.22%
- % Held by Insiders
- 13.80%
- % Held by Institutions
- 64.52%
- RVOL
- 0.07x
- Beta
- 0.95
Pipeline stages · 4 programs
PRT12396
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
PRT3789, pembrolizumabPD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
PRT7732
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
PRT2527, Zanubrutinib, Venetoclax
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-04 Estimated 50% readout ~2028-05-01 | Phase 1 | PRT12396 | Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Primary Myelofibrosis (PMF) | — | recruiting |
| 2026-01-28 | Phase 1 | PRT7732 | Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma | 42 | terminated |
| 2026-01-23 | Phase 2 | PRT3789, pembrolizumab | Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation | 6 | terminated |
| 2025-10-01 | Phase 1 | PRT3789, Docetaxel | Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation | 135 | completed |
| 2025-06-12 | Phase 1 | PRT2527, Zanubrutinib, Venetoclax | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome | 86 | completed |
Catalyst news & presentations · 21
- second half of 2026Guided 55%trial initiationsecondaryPhase 1KAT6A oral degrader · initiate phase 1 dose escalation studySEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryPhase 1PRT13722 · Phase 1 study initiation anticipated in H2 2026, pending IND clearance.SEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- by Q2 2026trial initiationsecondaryPhase 1PRT12396 · Phase 1 study of PRT12396 anticipated to initiate by Q2 2026SEC 8-K
- mid-2026regulatory submissionFiled (NDA/BLA)PRT13722 · File IND for PRT13722SEC 8-K
- first half of 2026regulatory submissionFiled (NDA/BLA)KAT6A degrader · IND filing for oral KAT6A degraderSEC 8-K
- first half of 2026regulatory submissionFiled (NDA/BLA)JAK2V617F JH2 inhibitor · IND filing for mutant selective JAK2V617F JH2 inhibitor programSEC 8-K
- mid-2026regulatory submissionFiled (NDA/BLA)PRLD-KAT6A degrader · IND filing for KAT6A selective degraderSEC 8-K
- 2Q 2026trial initiationsecondaryPhase 1PRLD-JAK2-VF+ · Phase 1 dose escalation and expansion in MPNsSEC 8-K
- April 20, 2026conferencedata presentationsecondaryPRT13722 · Preclinical data presented at AACR 2026 showing complete tumor regressions and improved safety.SEC 8-K
- 2026-02-03fda agreementPRT12396 · FDA cleared IND for PRT12396 to proceed with Phase 1 studySEC 8-K
- year end 2025readoutPhase 1PRT3789 · Final data from Phase 1 studySEC 8-K
- second half of 2025readoutPhase 1PRT7732 · Interim data update from Phase 1 dose escalation trialSEC 8-K
- December 6-9, 2025conferencedata presentationsecondarymCALR DAC · preclinical data oral presentation at ASH 67th Annual MeetingSEC 8-K
- December 6-9, 2025conferencedata presentationsecondaryJAK2V617F JH2 inhibitor · preclinical data oral presentation at ASH 67th Annual MeetingSEC 8-K
- 2025-11-30partnershipJAK2V617F program · Exclusive option agreement with IncyteSEC 8-K
- 2025-11-03trial discontinuedSMARCA2 degrader · Paused clinical development due to strategic portfolio shift.SEC 8-K
- 2025-11-01partnershipPRT12396 · Exclusive option agreement with IncyteSEC 8-K
- 2025-10-01partnershipdegrader payloads · expanded DAC collaboration with AbCellera Biologics, received license paymentSEC 8-K
- by year-end 2024readoutPhase 1PRT3789 · Conclude monotherapy dose escalation and identify dose for registrational trialsSEC 8-K
- December 2024conferencedata presentationsecondaryPhase 1PRT2527 · Interim Phase 1 data at American Society of Hematology Annual MeetingSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $8 (+107% upside) · 3 analysts
- 2026-05-04D. Boral CapitalBuy
- 2026-04-27HC Wainwright & Co.Buy
- 2026-03-11CitizensMarket Outperform
- 2025-09-23HC Wainwright & Co.Buy
- 2025-08-18JMP SecuritiesMarket Outperform
- 2025-05-05HC Wainwright & Co.Buy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-21Enterprise value to EBITDA forward of Prelude Therapeutics Incorporated – NASDAQ:PRLD - TradingView
- 2026-07-17Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why - Yahoo Finance
- 2026-07-17“LET’S HAINAN” Inaugural Media Salon in 2026 Launches over Waves - GlobeNewswire
- 2026-07-17“LET’S HAINAN” Inaugural Media Salon in 2026 Launches over Waves - GlobeNewswire
- 2026-07-15H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy By Investing.com - Investing.com Nigeria
- 2026-07-15H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy By Investing.com - Investing.com South Africa
- 2026-07-15H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy - Investing.com
- 2026-07-14Prelude Therapeutics Declines 7.6% as Key Support Level Comes into Play - High Reward Trades - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.